Arkolith/Insider Trading/TERN/Form 4

Gengos Andrew

Chief Financial OfficerTerns Pharmaceuticals, Inc. (TERN) · full profile →Form 4 · filed Jun 30, 2025
Net Buying
Open-Market Buys
$39K
Open-Market Sells
$0
Net Open-Market Flow
$39K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 27, 2025Buy(P)5K$3.93$20K25K
Jun 27, 2025Buy(P)5K$3.93$20K20K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-25-005120) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML